HUE051268T2 - Immunellenõrzõpont-gátló kombinációk - Google Patents

Immunellenõrzõpont-gátló kombinációk

Info

Publication number
HUE051268T2
HUE051268T2 HUE15793746A HUE15793746A HUE051268T2 HU E051268 T2 HUE051268 T2 HU E051268T2 HU E15793746 A HUE15793746 A HU E15793746A HU E15793746 A HUE15793746 A HU E15793746A HU E051268 T2 HUE051268 T2 HU E051268T2
Authority
HU
Hungary
Prior art keywords
immune checkpoint
checkpoint inhibitor
inhibitor combinations
combinations
immune
Prior art date
Application number
HUE15793746A
Other languages
English (en)
Hungarian (hu)
Inventor
Liv Marie Eike
Ketil Camilio
Baldur Sveinbjornsson
Laurence Zitvogel
Takahiro Yamazaki
Oystein Rekdal
John Sigurd Mjoen Svendsen
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506127.8A external-priority patent/GB201506127D0/en
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Publication of HUE051268T2 publication Critical patent/HUE051268T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HUE15793746A 2014-12-11 2015-11-04 Immunellenõrzõpont-gátló kombinációk HUE051268T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201422084 2014-12-11
GBGB1506127.8A GB201506127D0 (en) 2015-04-10 2015-04-10 Immune checkpoint inhibitor combinations
JP2015118495A JP6767096B2 (ja) 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ

Publications (1)

Publication Number Publication Date
HUE051268T2 true HUE051268T2 (hu) 2021-03-01

Family

ID=56384106

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15793746A HUE051268T2 (hu) 2014-12-11 2015-11-04 Immunellenõrzõpont-gátló kombinációk

Country Status (11)

Country Link
US (4) US11083774B2 (enExample)
EP (1) EP3230318B1 (enExample)
JP (1) JP6767096B2 (enExample)
AU (3) AU2015359881B2 (enExample)
DK (1) DK3230318T3 (enExample)
ES (1) ES2819282T3 (enExample)
HU (1) HUE051268T2 (enExample)
LT (1) LT3230318T (enExample)
PL (1) PL3230318T3 (enExample)
PT (1) PT3230318T (enExample)
WO (1) WO2016091487A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
EP3560513A4 (en) 2016-12-26 2020-10-14 National University Corporation Kobe University ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR
WO2018188761A1 (en) * 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
CN119868398A (zh) 2018-06-14 2025-04-25 株式会社明治 用于促进免疫检查点抑制疗法的组合物
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102841588B1 (ko) 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
CN110317245B (zh) * 2019-08-02 2021-04-09 郑州大学 Lag-3蛋白亲和环肽及其应用
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US20230037966A1 (en) * 2020-01-07 2023-02-09 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
AU2023413685A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan
EP4637799A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Medical products containing an aqueous formulation of a peptide
CN117402828A (zh) * 2023-04-13 2024-01-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种人肺癌脑转移瘤细胞系及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2328507A1 (en) 1998-05-04 1999-11-11 Thomas Jefferson University Use of a composition comprising tumor cells or tumor cell extracts for inducing an anti-tumor response in a mammalian patient
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US9410206B2 (en) * 2011-11-30 2016-08-09 John Wayne Cancer Institute Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
MX2017007535A (es) * 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ

Also Published As

Publication number Publication date
AU2015359881A1 (en) 2017-07-20
ES2819282T3 (es) 2021-04-15
US20240293506A1 (en) 2024-09-05
US12239686B2 (en) 2025-03-04
EP3230318B1 (en) 2020-06-24
US20230201305A9 (en) 2023-06-29
PT3230318T (pt) 2020-09-21
JP6767096B2 (ja) 2020-10-14
US11083774B2 (en) 2021-08-10
AU2015359881B2 (en) 2019-02-07
AU2019203199B2 (en) 2021-04-01
AU2019203199A1 (en) 2019-05-30
US20250332217A1 (en) 2025-10-30
DK3230318T3 (da) 2020-08-31
AU2021204356B2 (en) 2024-10-03
US20210401933A1 (en) 2021-12-30
EP3230318A1 (en) 2017-10-18
LT3230318T (lt) 2020-10-12
US20180264079A1 (en) 2018-09-20
WO2016091487A1 (en) 2016-06-16
AU2021204356A1 (en) 2021-07-22
PL3230318T3 (pl) 2021-03-08
JP2016128399A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
SG11201701322WA (en) Special effects techniques
IL251784A0 (en) Bromodomain inhibitors
AU361515S (en) Dishrack
IL239830B (en) Case
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
AU359704S (en) Case
AU362944S (en) Lapboard
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
PL3230318T3 (pl) Kombinacje inhibitora immunologicznego punktu kontrolnego
IL238537A0 (en) Multi-purpose frisbee-umbrella
GB2526680B (en) Runway arrangement
GB201411713D0 (en) S-detekt
GB201419650D0 (en) Modified heterocyclase
GB2523854B (en) Circuitry
GB201401005D0 (en) Inhibitor
GB2531245B (en) Ramp
GB201416600D0 (en) Glycobiological surfaces
GB201506127D0 (en) Immune checkpoint inhibitor combinations
AU5584P (en) Laniowa Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5285P (en) FLOMANRER Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi